Neurothera Labs (FRA:C0A) Scaled Net Operating Assets: -0.16 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C0A Neurothera Labs Inc FRA:C0A
32 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Scaled Net Operating Assets?

Neurothera Labs FRA:C0A +0.34% 32 Scaled Net Operating Assets is -0.16 as of Dec. 2025. GuruFocus rates FRA:C0A with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Neurothera Labs's operating assets for the quarter that ended in Dec. 2025 was €1.14 Mil. Neurothera Labs's operating liabilities for the quarter that ended in Dec. 2025 was €1.24 Mil. Neurothera Labs's Total Assets for the quarter that ended in Jul. 2025 was €0.65 Mil. Therefore, Neurothera Labs's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -0.16.


Neurothera Labs Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Scaled Net Operating Assets Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Scaled Net Operating Assets
0.00 -0.05 -0.00 -0.03 -0.12

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 -0.15 -0.14 -0.16

FRA:C0A vs LLY, JNJ, ABBV: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - General subindustry, Neurothera Labs's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurothera Labs Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Neurothera Labs's Scaled Net Operating Assets falls into.


FRA:C0A
32GF Score
Neurothera Labs Inc FRA:C0A
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Neurothera Labs's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jan. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jan. 2025 )
=(Operating Assets (A: Jan. 2025 )-Operating Liabilities (A: Jan. 2025 ))/Total Assets (A: Jan. 2024 )
=(0.001-0.104)/0.836
=-0.12

where

Operating Assets(A: Jan. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.721 - 0.72
=0.001

Operating Liabilities(A: Jan. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.104 - 0 - 0
=0.104

Neurothera Labs's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jul. 2025 )
=(1.137-1.239)/0.65
=-0.16

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.59 - 1.453
=1.137

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.037 - 0.494 - 0.304
=1.239

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.16 mean?
Neurothera Labs (FRA:C0A) has a Scaled Net Operating Assets of -0.16 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Neurothera Labs and its competitors.
Is Neurothera Labs' Scaled Net Operating Assets too high?
Neurothera Labs' current Scaled Net Operating Assets is -0.16. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Scaled Net Operating Assets compare to LLY and JNJ?
Neurothera Labs' Scaled Net Operating Assets of -0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Neurothera Labs and its competitors. Neurothera Labs's current Scaled Net Operating Assets is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (FRA:C0A) has a current Scaled Net Operating Assets of -0.16. The current Scaled Net Operating Assets is -0.16. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Neurothera Labs (FRA:C0A), the current Scaled Net Operating Assets is -0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Other Exchanges NTLX:Canada
Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score

Get the complete analysis for FRA:C0A

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price